Post-treatment with an ultra-low dose of NADPH oxidase inhibitor diphenyleneiodonium attenuates disease progression in multiple Parkinson’s disease models

Subpicomolar diphenyleneiodonium inhibits microglial NADPH oxidase with high specificity and shows great potential as a therapeutic agent for neurodegenerative diseases

(2014) Qingshan Wang et al.   GLIA

Macrophage Antigen Complex-1 Mediates Reactive Microgliosis and Progressive Dopaminergic Neurodegeneration in the MPTP Model of Parkinson's Disease

(2014) X. Hu et al.   JOURNAL OF IMMUNOLOGY

Substance P Exacerbates Dopaminergic Neurodegeneration through Neurokinin-1 Receptor-Independent Activation of Microglial NADPH Oxidase

(2014) Q. Wang et al.   JOURNAL OF NEUROSCIENCE

NADPH oxidase and aging drive microglial activation, oxidative stress, and dopaminergic neurodegeneration following systemic LPS administration

(2013) Liya Qin et al.   GLIA

Subsite Awareness in Neuropathology Evaluation of National Toxicology Program (NTP) Studies

(2013) Deepa B. Rao et al.   TOXICOLOGIC PATHOLOGY

Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems

(2013) Lars Brichta et al.   TRENDS IN NEUROSCIENCES

The immunology of neurodegeneration

(2012) Eva Czirr et al.   JOURNAL OF CLINICAL INVESTIGATION

Endogenous dynorphin protects against neurotoxin-elicited nigrostriatal dopaminergic neuron damage and motor deficits in mice

(2012) Qingshan Wang et al.   Journal of Neuroinflammation

NADPH oxidases: novel therapeutic targets for neurodegenerative diseases

(2012) Hui-Ming Gao et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Neuroinflammation and α-Synuclein Dysfunction Potentiate Each Other, Driving Chronic Progression of Neurodegeneration in a Mouse Model of Parkinson’s Disease

(2011) Hui-Ming Gao et al.   ENVIRONMENTAL HEALTH PERSPECTIVES

NSAID use and risk of Parkinson disease: a population-based case-control study

(2011) C. Becker et al.   EUROPEAN JOURNAL OF NEUROLOGY

HMGB1 Acts on Microglia Mac1 to Mediate Chronic Neuroinflammation That Drives Progressive Neurodegeneration

(2011) H.-M. Gao et al.   JOURNAL OF NEUROSCIENCE

Neurodegeneration and Inflammation in Parkinson's disease

(2011) Sudarshan Phani et al.   PARKINSONISM & RELATED DISORDERS

Reactive microgliosis: extracellular μ-calpain and microglia-mediated dopaminergic neurotoxicity

(2010) Shannon Levesque et al.   BRAIN

Microglia in neurodegenerative disease

(2010) V. Hugh Perry et al.   Nature Reviews Neurology

Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease

(2010) K. Xu et al.   NEUROSCIENCE

NSAID Use and the Risk of Parkinsonʼs Disease

(2009) Ali Samii et al.   DRUGS & AGING

Neuroprotection trials in Parkinson's disease: Systematic review

(2009) Robert G. Hart et al.   MOVEMENT DISORDERS

Classical Inhibitors of NOX NAD(P)H Oxidases Are Not Specific

(2008) Elisabetta Aldieri et al.   CURRENT DRUG METABOLISM

Endotoxin induces a delayed loss of TH-IR neurons in substantia nigra and motor behavioral deficits

(2008) Yuxin Liu et al.   NEUROTOXICOLOGY

NOX enzymes as novel targets for drug development

(2008) J. David Lambeth et al.   Seminars in Immunopathology

Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression

(2008) Hui-Ming Gao et al.   TRENDS IN IMMUNOLOGY